Adamantia Nikolaidi1, Vassiliki Kotoula2,3, Georgia-Angeliki Koliou4, Eleni Giannoulatou5,6, Kyriaki Papadopoulou3, Flora Zagouri7, George Pentheroudakis8,9, Helen Gogas10, Mattheos Bobos3, Kyriakos Chatzopoulos3, Georgios Oikonomopoulos11, Dimitrios Pectasides12, Emmanouil Saloustros13, Niki Arnogiannaki14, Irene Nicolaou15, Pavlos Papakostas16, Iliada Bompolaki17, Gerasimos Aravantinos18, Ilias Athanasiadis19, George Fountzilas3,20,21. 1. Oncology Department Mitera Hospital, Athens, Greece mantonikolaidi@gmail.com hecogoff@otenet.gr. 2. Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece. 5. Bioinformatics and Systems Medicine Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia. 6. The University of New South Wales, Kensington, NSW, Australia. 7. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 8. Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece. 9. Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece. 10. First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 11. Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece. 12. Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. 13. Department of Oncology, University Hospital of Larissa, Larissa, Greece. 14. Department of Surgical Pathology, Saint Savvas Anticancer Hospital, Athens, Greece. 15. Department of Histopathology, Agii Anagriri Hospital, Athens, Greece. 16. Oncology Unit, Hippokration Hospital, Athens, Greece. 17. Oncology Department, General Hospital of Chania, Chania, Greece. 18. Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. 19. Oncology Department Mitera Hospital, Athens, Greece. 20. Aristotle University of Thessaloniki, Thessaloniki, Greece. 21. German Oncology Center, Limassol, Cyprus.
Abstract
BACKGROUND/AIM: Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. We investigated the distribution and prognostic effect of mutations and tumor infiltrating lymphocyte (stromal TIL density) in young (≤35 years) and elderly (>65 years) early breast cancer patients. MATERIALS AND METHODS: Paraffin tumor genotypes of all clinical subtypes from 345 patients were examined. RESULTS: A total of 638 mutations were detected in 221 patients (64.1%). Compared to young, elderly patients presented with lower TIL density (p<0.001) but more TILs in TP53 mutated tumors (p=0.042). Mutation in one, rather than in 2 or more genes, conferred better outcome (DFS: HR=0.51, p=0.016; OS: HR=0.47, p=0.015) but the effect was age-independent. CONCLUSION: There are fewer TILs and different mutations patterns in tumors from elderly patients compared to young. Age and TIL-independent gene agnostic co-mutations affect patient outcome. Copyright
BACKGROUND/AIM: Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. We investigated the distribution and prognostic effect of mutations and tumor infiltrating lymphocyte (stromal TIL density) in young (≤35 years) and elderly (>65 years) early breast cancerpatients. MATERIALS AND METHODS:Paraffintumor genotypes of all clinical subtypes from 345 patients were examined. RESULTS: A total of 638 mutations were detected in 221 patients (64.1%). Compared to young, elderly patients presented with lower TIL density (p<0.001) but more TILs in TP53 mutated tumors (p=0.042). Mutation in one, rather than in 2 or more genes, conferred better outcome (DFS: HR=0.51, p=0.016; OS: HR=0.47, p=0.015) but the effect was age-independent. CONCLUSION: There are fewer TILs and different mutations patterns in tumors from elderly patients compared to young. Age and TIL-independent gene agnostic co-mutations affect patient outcome. Copyright